Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. by Costa, Francesco & Valgimigli, Marco
correspondence
n engl j med 373;13 nejm.org september 24, 2015 1271
occurred at 137 centers throughout the world in 
the phase 3 trial, which suggests that the skills 
necessary to safely administer the combination 
therapy are widely available.
Furthermore, and to Valsecchi’s point, among 
the 120 patients who discontinued combination 
therapy because of toxic effects, the response 
rate was 67.5%. To us, this supports the current 
guidelines for management of toxic effects and 
discontinuation of treatment, since it shows that 
high response rates can be observed in the con-
text of no treatment-related deaths. Longer follow-
up will be needed to assess the effect of treat-
ment discontinuation on overall survival.
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Long-Term Use of Ticagrelor in Patients with Prior  
Myocardial Infarction
To the Editor: In their report on the PEGASUS-
TIMI 54 (Prevention of Cardiovascular Events in 
Patients with Prior Heart Attack using Ticagrelor 
Compared to Placebo on the Background of Aspi-
rin–Thrombolysis in Myocardial Infarction 54) 
trial, Bonaca et al. (May 7 issue)1 suggest that the 
benefit of dual antiplatelet therapy comes at a 
cost of an increased risk of bleeding events. A dual 
antiplatelet regimen administered at an even 
lower dose than the one used in this study could 
confer a reduced risk of bleeding events and im-
proved secondary prophylaxis against recurrent 
ischemic events as compared with aspirin.
We successfully tested a strategy of alternate-
day administration of clopidogrel 1 year after 
percutaneous coronary intervention with place-
ment of a drug-eluting stent.2 We hypothesized 
that the degree of antiplatelet effect that was 
required to prevent very late stent thrombosis 
decreases with time as the stent undergoes endo-
thelialization — in other words, the therapeutic 
threshold that is required to prevent very late 
stent thrombosis decreases with time. The anti-
platelet effect of clopidogrel lasts 5 to 7 days. 
Typically, after the interruption of clopidogrel 
therapy, stent thrombosis occurs after 3 to 4 days, 
which signifies the recovery of enough platelet 
function to produce stent thrombosis (i.e., above 
the therapeutic threshold). The use of clopido-
grel every other day or a lower dose of ticagrelor 
among patients receiving a drug-eluting stent 
may be sufficient to cross the much reduced 
therapeutic threshold that is required to prevent 
very late stent thrombosis after 1 year and to 
avert recurrent coronary events from spontane-
ous plaque rupture without much bleeding risk 
(a so-called Goldilocks dose).
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To the Editor: Bonaca et al. report higher rates 
of cancer-related death among patients receiving 
either 90 mg or 60 mg of ticagrelor than among 
those receiving placebo (1.10% and 0.92% vs. 
0.76%) (Table S2 in the Supplementary Appendix, 
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available with the full text of the article at 
NEJM.org). Similar findings have been reported 
by Mauri et al.1 with an extended use of thieno-
pyridines beyond 1 year.
A pooled analysis of these two studies sug-
gests a significant relative increase of 41% in the 
number of cancer-related deaths among patients 
who were treated with extended dual antiplatelet 
therapy (Fig. 1). In this analysis, the number of 
patients who would need to be treated to cause 
one cancer death was 322. Could the author in-
dicate whether there was an imbalance in the 
diagnosis of cancer before and after randomiza-
tion in the two study groups? If this is not the 
case, the reason for an increase in cancer-related 
deaths with an extended duration of dual anti-
platelet therapy should be investigated.
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To the Editor: Bonaca et al. are missing the 
most important finding of the PEGASUS-TIMI 54 
study — namely, that drugs that cause excess 
bleeding also increase the risk of solid cancers. 
This study showed an increasing dose–response 
relationship for deaths from cancer: 77 in the 
group receiving 90 mg of ticagrelor and 64 in 
those receiving 60 mg of ticagrelor, as compared 
with 53 receiving placebo. In the Study of Platelet 
Inhibition and Patient Outcomes (PLATO), the 
administration of ticagrelor was too short and 
the follow-up was too incomplete to provide reli-
able data about cancer.1
A review of prasugrel by the Food and Drug 
Administration (FDA)2 first reported the associ-
ation between bleeding and solid cancers. In the 
Trial to Assess Improvement in Therapeutic 
Outcomes by Optimizing Platelet Inhibition with 
Prasugrel–Thrombolysis in Myocardial Infarction 
38 (TRITON-TIMI 38),3 the hazard ratios in the 
prasugrel group, as compared with the clopido-
grel group, for the incidence of solid cancers and 
death were both approximately 1.6 (P = 0.001). 
An FDA review 4 of the DAPT study documented 
that the relative risk of the incidence of a solid 
cancer was about 1.2 with clopidogrel and 1.3 with 
prasugrel, as compared with placebo. The rates 
of cancer-related death (relative risk, 2.2; P = 0.02) 
were higher with continued use of thienopyri-
dines.5 The latter FDA review4 also provides an 
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Figure 1. Pooled Analysis of Cancer-Related Deaths among Patients Receiving Extended Dual Antiplatelet Therapy, 
as Compared with Standard Therapy, in Two Studies.
In the trial by Mauri et al. (Dual Antiplatelet Therapy [DAPT] study), patients who had received 1 year of treatment 
with a thienopyridine (clopidogrel or prasugrel) were randomly assigned to continue receiving a thienopyridine or to 
receive a placebo for another 18 months. In the trial by Bonaca et al. (PEGASUS-TIMI 54), all patients were followed 
for a median of 33 months, including those receiving ticagrelor (who are included in the extended-therapy group in 
the pooled analysis) and those receiving placebo (who are included in the standard-therapy group). The size of the 
squares is proportional to the size of the study. The diamond incorporates the overall hazard ratio and 95% confi-
dence interval.
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